We are a science-driven global biotech company

Transforming Potential into Reality

Find out more

Innovation in 3 Generations

Monoclonal Antibody

Lemzoparlimab CD47
Uliledlimab CD73

Bi-Specific Antibody

Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB

Super Antibody

mRNA, Probody
AI Design, Alphabody

Monoclonal Antibody

Lemzoparlimab CD47
Uliledlimab CD73

Bi-Specific Antibody

Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB

Super Antibody

mRNA, Probody
AI Design, Alphabody

Latest News

Press Releases

2024.02.07

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

The agreement marks an important milestone to advance the Company’s intent to become a U.S.-based biotech.

2023.11.06

I-Mab Announces Participation at Jefferies and Piper Conferences in November

The Company will have presentations and one-to-one meetings during the upcoming two investor conferences.

2023.11.02

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

CD38 antibody felzartamab has been granted Breakthrough Therapy Designation by the U.S. FDA, following the Orphan Drug Designation received in May 2023.

Our Purposeful Journey to Bring Innovative Medicines to People We Serve

Founded

I-Mab was established in June 2016

Series A Financing

I-Mab completed Series A financing, raising $58 million

Merger & Series B Financing

Third Venture Biopharma and Tasgen merged to form I-Mab, raising $120 million in Series B Financing

Series C Financing

I-Mab successfully raised $227 million in Series C Financing

Nasdaq Listing

I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company

AbbVie Global Partnership

I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab

Private Placement with Hillhouse Capital-Led Consortium

I-Mab entered into $523 million private placement agreement with Hillhouse Capital-led consortium

Global Footprint

I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou

Jumpcan Partnership

I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China

Moving Forward Together

At I-Mab, we are tackling the most challenging scientific problems

Our People

“Clinical researchers are real life superheroes providing innovative treatments to those in need.”

I-Mab Employee

“I'm inspired by my colleagues' dedication to excellence in the work that we do; their kindness and care make it easy to work together on challenging projects.”

I-Mab Employee

“At I-Mab, gender inclusivity is not a tagline. The Company provides various platforms for female employees to flourish. We feel much supported in our personal and career development.”

I-Mab Employee